Studies on the in vivo effects of interferon-beta (IFN beta) therapy on autoreactive T cells have never been carried out in multiple (MS). We investigated the T cell response to myelin basic protein (MBP), before and after IFN-beta therapy, raising MBP-specific T cell lines (TCL) from the peripheral blood of six MS patients with a satisfactory response to the treatment. IFN beta did not affect the relative frequency and epitope specificity of the TCL. After IFN beta therapy, the production of interleukin-4 was decreased in MBP-stimulated TCL while the secretion of interferon-gamma was increased in unstimulated TCL. Interleukin-10 and tumor necrosis factor-alpha did not show significant variations. This finding supports recent suggestions about the complexity of the T helper 1/T helper 2 paradigm in MS other organ-specific autoimmune diseases. In fact, the beneficial effects of IFN beta do not exclude an immunostimulatory action that involve potentially autoreactive T cells. This has implications for future treatment options, including combination therapies. (C) 1999 Elsevier Science B.V. All rights reserved.

T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis / Ristori, Giovanni; Montesperelli, C; Gasperini, Claudio; Battistini, L; Borsellino, G; Buttinelli, Carla; Cannoni, S; Perna, A; Pozzilli, Carlo; Salvetti, Marco. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - sep 1;99(1)(1999), pp. 91-96. [10.1016/S0165-5728(99)00107-1]

T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis.

RISTORI, GIOVANNI;GASPERINI, claudio;BUTTINELLI, Carla;POZZILLI, Carlo;SALVETTI, Marco
1999

Abstract

Studies on the in vivo effects of interferon-beta (IFN beta) therapy on autoreactive T cells have never been carried out in multiple (MS). We investigated the T cell response to myelin basic protein (MBP), before and after IFN-beta therapy, raising MBP-specific T cell lines (TCL) from the peripheral blood of six MS patients with a satisfactory response to the treatment. IFN beta did not affect the relative frequency and epitope specificity of the TCL. After IFN beta therapy, the production of interleukin-4 was decreased in MBP-stimulated TCL while the secretion of interferon-gamma was increased in unstimulated TCL. Interleukin-10 and tumor necrosis factor-alpha did not show significant variations. This finding supports recent suggestions about the complexity of the T helper 1/T helper 2 paradigm in MS other organ-specific autoimmune diseases. In fact, the beneficial effects of IFN beta do not exclude an immunostimulatory action that involve potentially autoreactive T cells. This has implications for future treatment options, including combination therapies. (C) 1999 Elsevier Science B.V. All rights reserved.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/406162
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact